1. Assurance ofCardiovascular Risk Reduction comes from broad Clinical Experience 2. GALAXY Presentation - suggested execution 1 3. Is Lower Better?Relationship between LDL-C…

A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of a Monoclonal Antibody to PCSK9, SAR236553/REGN727, in Patients with Primary Hypercholesterolemia…

Roche Template The role of Phase I in the quest for “good”cholesterol - failure of the CETP modulator dalcetrapib Joint Conference 2013 of CPI | AGAH | BAPU | AHPPI Nice,…

Slide 1 ADA & ACC Consensus Statement Lipoprotein Management in Patients with Cardiometabolic Risk Thomas Dayspring, MD, FACP Clinical Assistant Professor of Medicine…

Evolving Scientific Insights into the Novel Therapeutic Target of PCSK9 Prof. John J.P. Kastelein, MD PhD FESC Dept. of Vascular Medicine Academic Medical Center / University…

A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of a Monoclonal Antibody to PCSK9, SAR236553/REGN727, in Patients with Primary Hypercholesterolemia…